Survodutide (10mg Vial) Dosage Protocol

Survodutide (10 mg Vial) Dosage Protocol

Quickstart Highlights

Survodutide (BI 456906) is an investigational dual GLP‑1/glucagon receptor agonist under development for obesity and metabolic liver disease[1][2]. In phase 2 trials, once‑weekly subcutaneous dosing (0.6–4.8 mg) produced dose‑dependent weight loss of 12.5–14.9% versus placebo over 46 weeks[1]. This educational protocol presents a once‑weekly subcutaneous titration approach using a practical dilution for clear insulin‑syringe measurements.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL (5000 mcg/mL) concentration.
  • Typical weekly range: 0.6–6.0 mg once weekly (gradual titration over 10–12 weeks).
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at ≤−20 °C (≤−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.
Survodutide Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing

Standard / Gradual Titration (2 mL = 5 mg/mL)

Route & Frequency: Subcutaneous injection once weekly (all clinical trials used weekly dosing)[1][2].

Week Weekly Dose (mg) Weekly Dose (mcg) Units (mL)
Weeks 1–2 0.6 mg 600 mcg 12 units (0.12 mL)
Weeks 3–4 1.2 mg 1200 mcg 24 units (0.24 mL)
Weeks 5–6 1.8 mg 1800 mcg 36 units (0.36 mL)
Weeks 7–8 2.4 mg 2400 mcg 48 units (0.48 mL)
Weeks 9–10 3.6 mg 3600 mcg 72 units (0.72 mL)
Weeks 11–12 4.8 mg 4800 mcg 96 units (0.96 mL)
Week 13+ 6.0 mg 6000 mcg 120 units (1.20 mL)*

*Note: The 6.0 mg maintenance dose (120 units / 1.20 mL) exceeds a standard 100‑unit (1 mL) insulin syringe. Use a 1 mL or 3 mL Luer‑lock syringe with appropriate needle, or administer as two separate injections.

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week weekly protocol with gradual titration.

  • Peptide Vials (Survodutide, 10 mg each):

    • 8 weeks ≈ 2 vials (~17 mg total)
    • 12 weeks ≈ 4 vials (~39 mg total)
    • 16 weeks ≈ 7 vials (~63 mg total)
  • Insulin Syringes (U‑100) or 1 mL Luer‑lock Syringes:

    • Per week: 1 syringe (once weekly)
    • 8 weeks: 8 syringes
    • 12 weeks: 12 syringes
    • 16 weeks: 16 syringes
  • Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.

    • 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
    • 12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
    • 16 weeks (7 vials): 14 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each week.

    • Per week: 2 swabs
    • 8 weeks: 16 swabs
    • 12 weeks: 24 swabs
    • 16 weeks: 32 swabs → recommend 1 × 100‑count box
Survodutide Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Concise summary of the once‑weekly regimen.

  • Goal: Support metabolic improvement and weight management through dual GLP‑1/glucagon receptor activation[1][3].
  • Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer as studied in phase 3 trials).
  • Dose Range: 0.6–6.0 mg weekly with gradual titration over 10–12 weeks.
  • Reconstitution: 2.0 mL per 10 mg vial (5 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; protect from light and avoid freeze–thaw.

Dosing Protocol

Suggested weekly titration approach based on clinical trial designs[1][2].

  • Start: 0.6 mg weekly; increase by 0.6 mg every 2 weeks as tolerated.
  • Target: 4.8–6.0 mg weekly by weeks 11–13.
  • Frequency: Once per week (subcutaneous).
  • Cycle Length: 12–16 weeks minimum; phase 3 trials extend to 48–72 weeks.
  • Timing: Same day each week; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at ≤−20 °C (≤−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); protect from light and avoid repeated freeze–thaw cycles.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document weekly dose, injection site, and any tolerability observations.
  • For doses exceeding 100 units (1.0 mL), consider using a 1 mL Luer‑lock syringe or splitting into two injections.

How This Works

Survodutide is a dual agonist that activates both GLP‑1 and glucagon receptors[1]. The GLP‑1 component enhances satiety and improves glycemic control, while the glucagon component increases energy expenditure and promotes hepatic lipid oxidation[3]. This dual mechanism is hypothesized to provide additive or synergistic effects on body weight and liver fat beyond GLP‑1 agonism alone[4]. In phase 2 trials, survodutide demonstrated substantial weight loss alongside improvements in liver enzyme markers[1][2].

Potential Benefits & Side Effects

Observations from clinical literature.

  • Dose‑dependent weight loss of 12.5–14.9% (vs placebo) over 46 weeks in phase 2 obesity trials[1].
  • Improvements in liver‑related biomarkers in NAFLD/NASH populations[2].
  • Meta‑analysis confirms consistent weight‑loss efficacy across multiple randomized controlled trials[5].
  • Adverse effects are primarily gastrointestinal: nausea, vomiting, diarrhea, and constipation (most common during dose escalation)[1][2].
  • Gradual titration helps mitigate GI tolerability issues.

Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, protein‑forward diet tailored to energy needs; GLP‑1 agonists can reduce appetite significantly.
  • Combine resistance training and aerobic activity to preserve lean mass during weight loss.
  • Stay well hydrated, especially if experiencing GI side effects.
  • Prioritize sleep and stress management to support metabolic health and adherence.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[9].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][8].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[10].

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References


  • Lancet Diabetes & Endocrinology (2024)
    — Le Roux et al. Phase 2 trial of once‑weekly SC survodutide (0.6–4.8 mg) in obesity; dose‑dependent weight loss of 12.5–14.9%
    View Source

  • Journal of Hepatology (2023)
    — Guo et al. Efficacy, tolerability, and pharmacokinetics of survodutide in NAFLD/NASH patients (cirrhosis cohort)
    View Source

  • Obesity (Silver Spring) (2024)
    — Wharton et al. SYNCHRONIZE‑1 & 2 phase 3 trial design for survodutide in obesity
    View Source

  • JACC: Heart Failure (2024)
    — Kosiborod et al. SYNCHRONIZE‑CVOT design: survodutide in patients at cardiovascular risk
    View Source

  • Diabetology & Metabolic Syndrome (2024)
    — Wan et al. Meta‑analysis of survodutide weight‑loss efficacy across randomized controlled trials
    View Source

  • Nature Reviews Endocrinology (2023)
    — GLP‑1/glucagon dual agonism: mechanistic overview and therapeutic potential
    View Source

  • CDC
    — Vaccine administration: subcutaneous route (angle/site guidance; no aspiration required)
    View Source

  • CDC (Subcut Injection PDF)
    — Technique diagram and site guidance for subcutaneous injections
    View Source

  • MedlinePlus (NIH)
    — Giving an insulin injection: patient guide for subcutaneous technique
    View Source

  • Veterans Affairs (2023)
    — Insulin injection: how to use and where to inject (injection sites, rotation guidance)
    View Source

  • NCBI Bookshelf
    — Best practices for injection (asepsis, preparation, and administration)
    View Source

  • Subcutaneous Drug Injection Review (PMC)
    — Pharmacologic considerations of the subcutaneous route
    View Source

  • Pure Lab Peptides
    — Survodutide (10 mg) product page (quality and batch documentation)
    View Source